Clinical implications of tumor-associated neovascularization and current antiangiogenic strategies for the treatment of malignancies of pancreas

Cancer

Volumn 78, Issue 3 SUPPL., 1996, Pages 680-687

  Pluda, James M ^a   Parkinson, David R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BATIMASTAT; CM 101; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 12; MARIMASTAT; PENTOSAN POLYSULFATE; TECOGALAN; THALIDOMIDE; THROMBOCYTE FACTOR 4; UNCLASSIFIED DRUG;

ANGIOGENESIS; HUMAN; NEOVASCULARIZATION (PATHOLOGY); PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; TUMOR BLOOD FLOW;

ANGIOGENESIS INDUCING AGENTS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS;

EID: 0029896570     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960801)78:3<680::AID-CNCR49>3.0.CO;2-S     Document Type: Review

References (88)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285(21):1182-6.
2. Folkman J, Klagsbrun M. Angiogenic factors. Science 1987; 235:442-7.
3. Inoue K, Korenaga H, Tanaka NG, Sakamoto N, Kadoya S. The sulfated polysaccharide-peptidoglycan complex potently inhibits embryonic angiogenesis and tumor growth in the presence of cortisone acetate. Carbohydr Res 1988; 181(135):135-42.
4. Herbert JM, Cottineau M, Driot F, Pereillo JM, Maffrand JP. Activity of pentosan polysulphate and derived compounds on vascular endothelial cell proliferation and migration induced by acidic and basic FGF in vitro. Biochem Pharmacol 1988;37(22):4281-8.
5. Ingber D, Fujita T, Kishimoto S, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348:555-7.
6. Maione TE, Gray GS, Petro J. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 1990;247(4938):77-9.
7. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324(1):1-8.
8. Nguyen M, Watanabe H, Budson AE, Richie JP, Hayes DF, Folkman J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994;86(5):356-61.
9. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82(1):4-6.
10. Hori A, Sasada R, Matsutani E. Suppression of solid tumor growth by immunoneutralizing monoclonal antibody against human basic fibroblast growth factor. Cancer Res 1991;51(22):6180-4.
11. Gross JL, Herblin WF, Dusak BA. Effects of modulation of basic fibroblast growth factor on tumor growth in vivo. J Natl Cancer Inst 1993;85(2):121-31.
12. Kim KJ, Li B, Winer J. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362(6423):841-4.
13. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
14. Millauer B, Shawver LK, Plate KH, Risau W, Ullrich A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994;367(6463):576-9.
15. Yamaoka M, Yamamoto T, Ikeyama S, Katsuichi S, Fujita T. Angiogenesis inhibitor TNP-470 (AGM-1470) potently inhibits the tumor growth of hormone-independent human breast and prostate carcinoma cell lines. Cancer Res 1993;53(21):5233-6.
16. Horak ER, Leek R, Klenk N. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992;340(8828):1120-4.
17. Weidner N, Folkman J, Pozza F. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84(24) : 1875-87.
18. Bosari S, Lee AK, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantitation and prognosis in invasive breast carcinoma. Hum Pathol 1992;23(7):755-61.
19. Gasparini G, Weidner N, Bevilacqua P. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12(3): 454-66.
20. Fregene TA, Khanuja PS, Noto AC. Tumor-associated angiogenesis in prostate cancer. Anticancer Res 1993;13(6B):2377-81.
21. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143(2):401-9.
22. Brawer MK, Deering RE, Brown M, Preston SD, Bigler SA. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994;73(3):678-87.
23. Gasparini G, Weidner N, Maluta S. Intratumoral microvessel density and p53 protein: correlation with metastasis in head-and-neck squamous-cell carcinoma. Int J Cancer 1993; 55(5):739-44.
24. Barnhill RL, Fandrey K, Levy MA, Mihm MJ, Hyman B. Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma. Lab Invest 1992;67(3):331-7.
25. Macchiarini P, Fontanini G, Hardin MJ, Squartini F, Angeletti CA. Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet 1992;340(8812):145-6.
26. Macchiarini P, Fontanini G, Dulmet E. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 1994;57(6):1534-9.
27. Olivarez D, Ulbright T, DeRiese W. Neovascularization in clinical stage A testicular germ cell tumor: prediction of metastatic disease. Cancer Res 1994;54(10):2800-2.
28. Bochner BH, Cote RJ, Weidner N. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 1995;87(21):1603-12.
29. Frank RE, Saclarides TJ, Leurgans S, Speziale NJ, Drab EA, Rubin DB. Tumor angiogenesis as a predictor of recurrence and survival in patients with node-negative colon cancer. Ann Surg 1995;222(6):695-9.
30. Li VW, Folkerth RD, Watanabe H. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994;344(8915):82-6.
31. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
32. Liotta LA, Kleinerman J, Saidel GM. Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation. Cancer Res 1974;34(5):997-1004.
33. Yamanaka Y, Friess H, Buchler M. Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res 1993;53(21):5289-96.
34. Kobrin MS, Yamanaka Y, Friess H, Lopez ME, Korc M. Aberrant expression of type I fibroblast growth factor receptor in human pancreatic adenocarcinomas. Cancer Res 1993; 53(20):4741-4.
35. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359(6398):843-5.
36. Berkman RA, Merrill MJ, Reinhold WC. Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 1993;91(1):153-9.
37. Abe T, Okamura K, Ono M. Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis. J Clin Invest 1993;92(1):54-61.
38. Morrison RS, Yamaguchi F, Bruner JM, Tang M, McKeehan W, Berger MS. Fibroblast growth factor receptor gene expression and immunoreactivity are elevated in human glioblastoma multiforme. Cancer Res 1994;54(10):2794-9.
39. Brown LF, Berse B, Jackman RW. Increased expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in kidney and bladder carcinomas. Am J Pathol 1993; 143(5):1255-62.
40. Nanus DM, Schmitz DB, Motzer RJ. Expression of basic fibroblast growth factor in primary human renal tumors: correlation with poor survival. J Natl Cancer Inst 1993; 85(19):1597-9.
41. Takahashi A, Sasaki H, Kim SJ. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res 1994;54(15):4233-7.
42. Schultz HS, Haghayegh S. Beta-fibroblast growth factor expression in human and murine squamous cell carcinomas and its relationship to regional endothelial cell proliferation. Cancer Res 1993;53(6):1444-9.
43. Gitay-Goren H, Halaban R, Neufeld G. Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors. Biochem Biophys Res Commun 1993; 190(3):702-8.
44. New BA, Yeoman LC. Identification of basic fibroblast growth factor sensitivity and receptor and ligand expression in human colon tumor cell lines. J Cell Physiol 1992; 150(2):320-6.
45. Brown LF, Berse B, Jackman RW. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53(19):4727-35.
46. Li D, Bell J, Brown A, Berry CL. The observation of angiogenin and basic fibroblast growth factor gene expression in human colonic adenocarcinomas, gastric adenocarcinomas, and hepatocellular carcinomas. J Pathol 1994;172(2):171-5.
47. Fujimoto K, Ichimori Y, Kakizoe T. Increased serum levels of basic fibroblast growth factor in patients with renal cell carcinoma. Biochem Biophys Res Commun 1991; 180(1):386-92.
48. Nguyen M, Watanabe H, Budson AE, Richie JP, Folkman J. Elevated levels of the angiogenic peptide basic fibroblast growth factor in urine of bladder cancer patients. J Natl Cancer Inst 1993;85(3):241-2.
49. Soutter AD, Nguyen M, Watanabe H, Folkman J. Basic fibroblast growth factor secreted by an animal tumor is detectable in urine. Cancer Res 1993;53(21):5297-9.
50. Kondo S, Asano M, Suzuki H. Significance of vascular endothelial growth factor/vascular permeability factor for solid tumor growth, and its inhibition by the antibody. Biochem Biophys Res Commun 1993;194(3):1234-41.
51. Klein-Soyer C, Beretz A, Cazenave J-P. Sulfated polysaccharides modulate effects of acidic and basic fibroblast growth factors on repair of injured confluent human vascular endothelium. Arteriosclerosis 1989;9(2):147-53.
52. Wellstein A, Lupu R, Zugmaier G. Autocrine growth stimulation by secreted Kaposi fibroblast growth factor but not by endogenous basic fibroblast growth factor. Cell Growth Differ 1990; 1:63-71.
53. Wellstein A, Zugmaier G, Califano JA, Kern F, Paik S, Lippman ME. Tumor growth dependent on Kaposi's sarcomaderived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst 1991;83(10):716-20.
54. Zugmaier G, Lippman ME, Wellstein A. Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst 1992;84(22):1716-24.
55. Pluda JM, Shay LE, Foli A. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993;85(19): 1585-92.
56. Hanson FR, Eble TE. An antiphage agent isolated from Aspergillus sp. J Bacterial 1949;58:527-9.
57. Kusaka M, Sudo K, Fujita T. Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Commun 1991;174(3):1070-6.
58. Brem H. Ingber D, Blood CH, Bradley D, Urioste S, Folkman J. Suppression of tumor metastasis by angiogenesis inhibition. Surg Forum 1991;42:439-41.
59. Kusaka M, Sudo K, Matsutani E. Cytostatic ionhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470). Br J Cancer 1994;69:212-16.
60. 1 phase of the cell cycle. Cancer Res 1994;54:2073-6.
61. Brem H, Folkman J. Analysis of experimental antiangiogenic therapy. J Ped Surg 1993;28(3):445-51.
62. Yanase T, Tamura M, Fujita K, Kodama S, Tanaka K. Inhibitory effect of angiogenesis inhibitor TNP-470 on tumor growth and metastasis of human cell lines in vitro and in vivo. Cancer Res 1993;53:2566-70.
63. Yamaoka M, Yamamoto T, Masaki T, Ikeyama S, Sudo K, Fujita T. Inhibition of tumor growth and metastasis of rodent tumors by the angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol TNP-470: AGM-1470). Cancer Res 1993;53:4262-7.
64. Takamiya Y, Friedlander RM, Brem H, Malick A, Martuza RL. Inhibition of angiogenesis and growth of human nerve-sheath tumors by AGM-1470. J Neurosurg 1993;78:470-6.
65. Sharpe RJ, Byers HR, Scott CF, Bauer SI, Maione TE. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4. J Natl Cancer Inst 1990;82(10):848-53.
66. Sato Y, Abe M, Takaki R. Platelet factor 4 blocks the binding of basic fibroblast growth factor to the receptor and inhibits the spontaneous migration of vascular endothelial cells. Biochem Biophys Res Commun 1990;172(2):595-600.
67. Watson JB, Getzler SB, Mosher DF. Platelet factor 4 modulates the mitogenic activity of basic fibroblast growth factor. J Clin Invest 1994;94(1):261-8.
68. Maione TE, Gray GS, Hunt AJ, Sharpe RJ. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res 1991;51(8):2077-83.
69. Tanaka NG, Sakamoto N, Inoue K. Antitumor effects of an antiangiogenic polysaccharide from an Arthrobacter species with or without a steroid. Cancer Res 1989;49(23):6727-30.
70. Tanaka NG, Sakamoto N, Korenaga H, Inoue K, Ogawa H, Osada Y. The combination of a bacterial polysaccharide and tamoxifen inhibits angiogenesis and tumour growth, Int J Radiat Biol 1991;60(1-2):79-83.
71. Nakamura S, Sakurada SS, Salahuddin Z. Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science 1992;255:1437-40.
72. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 1994;91(9):4082-5.
73. Davies B, Brown PD, East N, Crimmin MJ, Balkwill FR. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Res 1993;53(9):2087-91.
74. Wang X, Fu X, Brown PD, Crimmin MJ, Hoffman RM. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Res 1994;54(17):4726-8.
75. Chirivi RG, Garofalo A, Crimmin MJ. Inhibition of the metastatic spread and growth of B16-BL6 murine melanoma by a synthetic matrix metalloproteinase inhibitor, Int J Cancer 1994;58(3):460-4.
76. Hellerqvist CG, Thurman GB, Page DL. Antitumor effects of GBS toxin: a polysaccharide exotoxin from group B betahemolytic streptococcus. J Cancer Res Clin Oncol 1993; 120(1-2):63-70.
77. Hellerqvist CG, Thurman GB, Russell BA, editors. Antitumor effects of group B streptococcus toxin achieved by induction of a targeted inflammatory reaction [abstract]. The 18th International Congress of Chemotherapy; Stockholm, Sweden, abstr. 1541.
78. Thurman GB, Russel BA, York GE. Effects of group B Streptococcus toxin on long-term survival of mice bearing transplanted Madison lung tumors. J Cancer Res Clin Oncol 1994;120(8):479-84.
79. DeVore R, Johnson DR, Hellerqvist C. A phase I study of the anti-neovascularization drug CM-101 [abstract]. Proc Am Soc Clin Oncol 1995;14:487.
80. Hellerqvist C, DeVore R, Thurman G. Cytokine production in cancer patients receiving the anti-neovascularization drug CM-101 [abstract]. Proc Am SocClin Oncol 1995; 14:488.
81. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994;84(12):4008-27.
82. Scott P. IL12: initiation cytokine for cell-mediated immunity. Science 1993;260:496-7.
83. Clerici M, Lucey DR, Berzofsky JA. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993;262:1721-4.
84. Brunda MJ, Luistro L, Warrier RR. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178(4):1223-30.
85. Voest EE, Kenyon BM, MS OR, Truitt G, RJ DA, Folkman J. Inhibition of angiogenesis in vivo by interleukin 12 [comments]. J Natl Cancer Inst 1995;87(8):581-6.
86. Angiolillo AL, Sgadari C, Taub DD. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995;182(1):155-62.
87. Teicher BA, Sotomayor EA, Huang ZD. Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 1992;52(23):6702-4.
88. Teicher BA, Holden SA, Ara G, Northey D. Response of the FSall fibrosarcoma to antiangiogenic modulators plus cytotoxic agents. Anticancer Res 1993; 13(6A):2101-6.